Vyome Holdings HIND
NASDAQ HIND
$2.25 -0.03 (-1.32%)
As of: Aug 21, 2026 · 3:38 PM EDT

Vyome Holdings (HIND) Cash from Financing Activities (2015 - 2026)

Vyome Holdings (HIND) posted quarterly Cash from Financing Activities of $5.3 million for Q1 2026, up 3205.54% year-over-year from $160000.0 in Q1 2025, and up 592.24% quarter-over-quarter from $764020.0 in Q4 2025.

Vyome Holdings (HIND) Cash from Financing Activities (2015 - 2026) Analysis & Trends

Vyome Holdings' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $5.3 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 3205.54% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $13.8 million (up 118.97% YoY), while the FY2025 annual figure was $8.7 million, up 1140.05% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $5.3 million, up from $764020.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $10.2 million in Q1 2023, with the low at -$2.2 million in Q3 2025.
  • The 5-year median for Cash from Financing Activities is $638000.0 (2022), against an average of $2.5 million.
  • The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 11366.67% in 2023, then soared 3205.54% in 2026.
  • Vyome Holdings' Cash from Financing Activities stood at $638000.0 in 2022, then surged by 755.96% to $5.5 million in 2023, then slumped by 99.02% to $53466.0 in 2024, then surged by 1328.98% to $764020.0 in 2025, then surged by 592.24% to $5.3 million in 2026.
  • Business Quant data shows HIND's Cash from Financing Activities at $5.3 million in Q1 2026, $764020.0 in Q4 2025, and -$2.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 Vyome Holdings 16.07 Mn 8.18 Mn 11,658.00 -3,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -3,000.00
Jun 30, 2026 -3,000.00
Mar 31, 2026 5.29 Mn
Mar 31, 2026 5.29 Mn
Dec 31, 2025 764,020.00
Dec 31, 2025 764,020.00
Sep 30, 2025 -2.16 Mn
Sep 30, 2025 -2.16 Mn
Jun 30, 2025 9.89 Mn
Jun 30, 2025 9.89 Mn
Mar 31, 2025 160,000.00
Mar 31, 2025 160,000.00
Dec 31, 2024 53,466.00
Dec 31, 2024 53,466.00
Sep 30, 2024 620,485.00
Sep 30, 2024 620,485.00
Dec 31, 2023 5.46 Mn
Dec 31, 2023 5.46 Mn
Sep 30, 2023 -338,000.00
Sep 30, 2023 -338,000.00